Mayne Pharma Group Ltd logo

Mayne Pharma Group Ltd - ADR

OTCPK:MYPHY (Australia)   ADR
$ 0.00 0 (0%) 09:42 AM EST
At Loss
P/B:
0.75
Market Cap:
$ 328.83M
Enterprise V:
$ 461.83M
Volume:
-
Avg Vol (2M):
-
Also Trade In:
Volume:
-
At Loss
Avg Vol (2M):
-
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for MYPHY ( Mayne Pharma Group Ltd ) from 2017 to Jun 08 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Mayne Pharma Group stock (MYPHY) PE ratio as of Jun 08 2024 is 0. More Details

Mayne Pharma Group Ltd (MYPHY) PE Ratio (TTM) Chart

To

Mayne Pharma Group Ltd (MYPHY) PE Ratio (TTM) Historical Data

Total 0
  • 1
Mayne Pharma Group PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data

Mayne Pharma Group Ltd (MYPHY) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Mayne Pharma Group Ltd logo
Mayne Pharma Group Ltd
NAICS : 325412 SIC : 2834
ISIN : US5784511066

Share Class Description:

MYPHY: ADR
Description
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Branded Products (BPD) and Portfolio Products Division (PPD). The Portfolio Products Division distributes dermatology products (branded and generic) in the US on a portfolio basis, The Branded Products Division distributes branded women's health products in the US. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.